Global brokerage Bernstein has initiated coverage on India’s healthcare sector, projecting it could quadruple to $195 billion in a decade. The firm highlights innovation in complex therapies and AI adoption as key drivers, naming Zydus Lifesciences, Lupin, and Sun Pharma as beneficiaries while cautioning on other players.
Global financial services firm Bernstein has initiated coverage on India’s healthcare sector, setting an optimistic tone for the industry over the next ten years. The brokerage identifies India as a primary hub for advanced biopharmaceutical manufacturing, anticipating that innovation and technology will unlock significant global value.
Growth Drivers and Market Potential
Bernstein estimates that the global market for specialized medical treatments—including weight management, preventive care, and digital health—could expand by $400 billion. The brokerage expects Indian companies to capture a significant portion of this growth by moving beyond traditional generics. Key areas identified for expansion include metabolic peptides, RNA therapies, and drug-device combinations.
Beyond product innovation, the firm points to the adoption of Generative AI as a major factor for profitability. Bernstein projects that integrating AI into research and operations could increase profit margins by 3 to 4 percentage points. Additionally, Indian firms are shifting toward a stronger quality culture, which is expected to support the export of more complex, high-value medicines to regulated markets.
Sector Valuation and Stock Outlook
While the Pharma Nifty index is currently trading at valuation multiples above its ten-year average of 30.5x, Bernstein notes that its favored stocks are positioned differently. The brokerage suggests that the broader market may be overly concerned with short-term pricing pressure in the US generics market, potentially overlooking the long-term impact of new, innovation-led revenue streams.
Bernstein has issued an 'Outperform' rating for Zydus Lifesciences, Lupin, and Sun Pharma. Zydus Lifesciences is labeled the top pick, credited for its strong execution and specialized pipeline. Conversely, the firm assigned a 'Market-Perform' rating to Aurobindo Pharma and an 'Underperform' rating to Biocon and Mankind Pharma.
Important Investor Context
Investors should note that shifting toward innovation-led therapies involves higher development costs and regulatory risks compared to standard generic manufacturing. While Bernstein highlights a positive long-term trajectory, the performance of these companies will depend on their ability to successfully execute complex R&D projects and maintain global quality standards.
Looking ahead, the primary monitorables for investors will include the successful commercialization of these niche therapies, the actual margin gains realized through AI implementation, and the companies' ability to navigate evolving global regulatory requirements. Changes in US drug pricing policies and domestic regulatory stability also remain factors that could influence the speed of growth in the sector.